Retinal vein occlusion

1. Retinal vein occlusion is associated with retinal age gap in humans (mean difference = 1.42 years, p = 0.037).

   Humansaffected eyes vs fellow eyes

   Retinal age gap in unilateral retinal diseases with unaffected fellow eye: phakia and vascular pathology impact retinal age prediction · Japanese journal of ophthalmology · 3 Oct 2026

Retinal age gap →

1. GLP-1 receptor agonists lower the risk of retinal vein occlusion in humans (HR = 0.73, 0.54-0.98).

   Reviewcompared to dipeptidyl-peptidase-4 (DPP-4) inhibitors

   Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis · Eye (London, England) · 24 Sep 2026

GLP-1 receptor agonists →

1. Metformin lowers the risk of retinal vein occlusion in humans (HR = 0.46, 0.30-0.73).

   Reviewmonotherapy in cohort study

   Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis · Eye (London, England) · 24 Sep 2026

Metformin →

1. Statins lower the risk of retinal vein occlusion in humans (OR = 0.65 (95% CI = 0.53-0.79)).

   Reviewmeta-analysis of observational studies

   Potential protective associations of antidiabetic and lipid-lowering therapies with retinal vein occlusion risk: a systematic review and meta-analysis · Eye (London, England) · 24 Sep 2026

Statins →